Last updated on August 2017

A Study to Assess the Safety Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours


Brief description of study

This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.

Detailed Study Description

This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours refractory to standard therapy or for which no standard therapy exists. The safety, tolerability, and preliminary anti-tumour activity of ascending doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and Tremelimumab will be investigated. Once safety and tolerability have been established for the relevant dose, expansion cohorts will commence in order to further evaluate safety, tolerability, and provide a preliminary evaluation of the mechanism of action and anti-tumour activity of the drug combination. Mandatory paired biopsy expansion cohorts will be tumour-type specific. Expansion cohorts will open independently for double and triple combination treatments.

Clinical Study Identifier: NCT02586987

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

AstraZeneca Clinical Study Information Center

Research Site
Birmingham, AL United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Scottsdale, AZ United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Los Angeles, CA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Chicago, IL United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Boston, MA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Ann Arbor, MI United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Detroit, MI United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Saint Louis, MO United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Las Vegas, NV United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
New Brunswick, NJ United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
New York, NY United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Charlotte, NC United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Philadelphia, PA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Pittsburgh, PA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Salt Lake City, UT United States
  Connect »